Order results by:
| Issue | Title | |
| Vol 13, No 6 (2021) | Possibilities of using amantadines in the setting of the novel coronavirus infection in patients with Parkinson's disease | Abstract similar documents |
| E. A. Katunina, Yu. N. Bezdolnyi, N. N. Shipilova | ||
| "... adamantanes. Objective: to assess possible mechanisms of antiviral action of amantadine and memantine ..." | ||
| Vol 14, No 6 (2022) | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study | Abstract similar documents |
| Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova | ||
| "... Amantadine has begun to be used as a possible alternative in COVID-19 therapy to mitigate its ..." | ||
| Vol 8, No 1 (2016) | Multiple sclerosis-related fatigue and possibilities of its correction | Abstract similar documents |
| N. Yu. Lashch, A. N. Boiko | ||
| "... симптоматической терапии при РС, является амантадин. В статье представлены данные рандомизированных клинических ..." | ||
| Vol 6, No 4 (2014) | Dopaminergic deficiency syndrome in the picture of severe brain injury in the presence of protracted depression of consciousness | Abstract similar documents |
| M. V. Chelyapina, E. V. Sharova, O. S. Zaitsev | ||
| "... and anterior temporal regions. The administration of amantadine sulfate was followed by an increase (even ..." | ||
| Vol 15, No 6 (2023) | Effect of dopaminergic therapy on lacrimation in Parkinson's disease | Abstract similar documents |
| A. A. Pilipovich, O. V. Vorob'eva, S. A. Makarov, A. V. Kuchuk | ||
| "... to Hoehn and Yahr (H&Y) receiving therapy with levodopa (n=17), amantadines (n=13) and dopamine receptor ..." | ||
| Vol 17, No 2 (2025) | Drug-induced dyskinesia when taking Fluvoxamine | Abstract similar documents |
| A. A. Katok, D. M. Khasanova, I. A. Khasanov | ||
| "... at a dose of 225 mg/day. As a treatment of acute motor disorders caused by Fluvoxamin, the use of amantadine ..." | ||
| Vol 13, No 3 (2021) | Profile and frequency of antiparkinsonian drugs adverse reactions: a systematic review and meta-analysis | Abstract similar documents |
| A. A. Tappakhov, T. E. Popova, A. I. Vasilev, T. G. Govorova, Yu. I. Khabarova, K. A. Timofeeva, N. A. Schnaider | ||
| "... hypertension was present in 9.6% of patients prescribed with piribedil. Amantadine compared with pramipexole ..." | ||
| Vol 16, No 2 (2024) | Efficacy of antiparkinsonian therapy in tremor correction according to tremorography | Abstract similar documents |
| V. A. Bogacheva, D. V. Zakharov, V. A. Mikhailov | ||
| "... ), anticholinergics (biperiden), amantadines (amantadine sulfate). Before starting treatment and after completion ..." | ||
| Vol 12, No 3 (2020) | Memantine: procognitive and antinegative effects in mental illness (a literature review) | Abstract similar documents |
| D. V. Romanov, P. G. Yuzbashyan | ||
| "... According to the instruction approved in the Russian Federation, Akatinol Memantine is indicated ..." | ||
| Vol 12, No 6 (2020) | Use of akatinol memantine for the treatment of Korsakoff's syndrome: a clinical case | Abstract similar documents |
| N. A. Tyuvina, T. N. Maksimova, S. V. Prokhorova, V. O. Vysokova | ||
| "... withdrawal period is the basis for KS development. Memantine, a noncompetitive NMDA receptor antagonist, has ..." | ||
| Vol 14, No 5 (2022) | Dysphagia in Alzheimer's disease | Abstract similar documents |
| N. N. Koberskaya | ||
| "... . We describe a clinical case of severe AD in which a dispersible form of memantine, Memoritab ..." | ||
| Vol 14, No 3 (2022) | Neuropsychiatric disorders correction in Alzheimer's disease | Abstract similar documents |
| N. N. Koberskaya | ||
| "... . It seems appropriate to use memantine (akatinol memantine) in patients with neuropsychiatric symptoms of AD ..." | ||
| Vol 9, No 4 (2017) | Current approaches to diagnosing and treating major neurocognitive disorder | Abstract similar documents |
| A. A. Kulesh, V. V. Shestakov | ||
| "... of akatinol memantine to treat this disorder and the issues related to the comprehensive management ..." | ||
| Vol 14, No 6 (2022) | Alzheimer's disease and COVID-19 | Abstract similar documents |
| N. N. Koberskaya, F. A. Roshchin | ||
| "... -19 and AD is discussed. The rationale for the use of memantine (akatinol memantine) in patients ..." | ||
| Vol 15, No 3 (2023) | Parkinson’s disease. Focus on early stages | Abstract similar documents |
| E. A. Katunina, Z. A. Zalyalova, D. V. Pokhabov, M. Z. Ivanova, A. M. Semenova | ||
| "... (ADR), amantadines, MAO-B inhibitors. The mechanisms of ADR action, the possibility of their influence ..." | ||
| Vol 14, No 2 (2022) | Early-onset Alzheimer's disease | Abstract similar documents |
| A. B. Lokshina, D. A. Grishina, A. V. Obukhova | ||
| "... Akatinol Memantine administration are shown. The main problems of management of young patients with AD ..." | ||
| Vol 13, No 5 (2021) | Treatment of cognitive impairment in arterial hypertension | Abstract similar documents |
| Yu. A. Starchina, K. S. Sleptcova | ||
| "... by controlling blood pressure. The review discusses the use of memantine – a reversible inhibitor of NMDA ..." | ||
| Vol 14, No 3 (2022) | Combined therapy for Alzheimer's disease | Abstract similar documents |
| V. V. Zakharov, A. V. Lokshina, N. V. Vakhnina | ||
| "... to the problem of combined therapy of dementia in AD with donepezil and memantine are considered. The fixed ..." | ||
| Vol 14, No 4 (2022) | Cognitive impairment in patients with coronavirus infection | Abstract similar documents |
| Y. A. Starchina, O. V. Kosivtsova | ||
| "... COVID-19, memantine (akatinol memantine) is recommended. ..." | ||
| Vol 11, No 4 (2019) | Errors in the management of patients with Alzheimer's disease: analysis of problems and ways of their solution | Abstract similar documents |
| A. Yu. Emelin, I. V. Litvinenko, V. Yu. Lobzin | ||
| Vol 7, No 3 (2015) | Treatment for Alzheimer's diseases | Abstract similar documents |
| Nina Arkadyevna Tyuvina, V. V. Balabanova | ||
| Vol 9, No 3 (2017) | Current views of the risk factors, diagnosis, and therapy of Alzheimer's disease (according to the proceedings of the Alzheimer's Association International Conference, London, 2017) | Abstract similar documents |
| N. N. Koberskaya | ||
| Vol 4, No 2S (2012): Сognitive and other neuropsychiatric disorders | Cognitive impairments in patients with prior ischemic stroke | Abstract similar documents |
| V. A. Parfenov, M. A. Cherdak, N. V. Vakhnina, S. V. Verbitskaya, L. Yu. Nikitina | ||
| "... , and behavioral disorders. The experience with akatinol memantine used in postischemic dementia has been found ..." | ||
| Vol 5, No 2S (2013): Special issue "Stroke" | Management of patients with post-stroke dementia | Abstract similar documents |
| Svetlana Viktorovna Verbitskaya | ||
| "... the efficacy of central acetylcholinesterase inhibitors and the NMDA receptor antagonist akatinol memantine ..." | ||
| Vol 14, No 2 (2022) | Association between redox imbalance, pterin metabolism markers, and early extrapyramidal side effects of antipsychotics in schizophrenia: pilot study | Abstract similar documents |
| T. V. Zhilyaeva, D. S. Shvachkina, A. S. Piatoikina, E. S. Zhukova, O. V. Kostina, T. G. Shcherbatyuk, G. E. Mazo | ||
| "... in patients prescribed with amantadine was lower than in other participants. Conclusion. Early AP-induced ..." | ||
| Vol 13, No 6 (2021) | Treatment of noncognitive neuropsychiatric disorders in Alzheimer's disease | Abstract similar documents |
| A. B. Lokshina, D. A. Grishina | ||
| "... . As an example, we present a case report of a female patient with mild dementia in AD in whom Akatinol memantine ..." | ||
| Vol 13, No 4 (2021) | Influence of genetic and comorbid emotional-affective factors on pre-mild cognitive decline in middle-aged patients | Abstract similar documents |
| N. N. Koberskaya, T. M. Ostroumova, V. A. Perepelov, D. S. Smirnov | ||
| Vol 15, No 1 (2023) | Modern aspects of diagnosis and treatment of cognitive impairments (literature review) | Abstract similar documents |
| A. B. Lokshina, V. V. Zakharov, N. V. Vakhnina | ||
| "... . The possibilities of modern neuroprotective and symptomatic therapy of CI, the place of akatinol memantine ..." | ||
| Vol 12, No 4 (2020) | Possibilities of drug therapy for vascular cognitive impairment: a critical view and possible compromises | Abstract similar documents |
| A. Yu. Emelin, V. Yu. Lobzin | ||
| "... deficit. The basic anti-dementia medications (akatinol memantine and acetylcholinesterase inhibitors ..." | ||
| Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Alzheimer's disease | Abstract similar documents |
| N. N. Koberskaya | ||
| "... for AD. The efficacy of memantine (akatinol memantine) and the expediency of its use at different stages ..." | ||
| Vol 10, No 3 (2018) | Alzheimer's disease: some pharmacological and non-pharmacological approaches to correcting neuropsychiatric disorders | Abstract similar documents |
| E. G. Mendelevich | ||
| "... . The possibilities of drug therapy for NPDs are demonstrated. The role of akatinol memantine in correcting a number ..." | ||
| Vol 6, No 2S (2014): Special issue "Stroke" | NMDA receptor antagonists in the treatment of patients with vascular cognitive imprairments | Abstract similar documents |
| I.S. Preobrazhenskaya | ||
| "... The paper discusses the possibilities of using the NMDA receptor antagonist memantine in patients ..." | ||
| Vol 6, No 1 (2014) | Dementia of the Alzheimer type: current state of the problem | Abstract similar documents |
| N.A. Tyuvina, V.V. Balabanova | ||
| Vol 5, No 1 (2013) | Practical aspects of the use of extended-release ropinirole (requip modutab) in the treatment of Parkinson’s disease | Abstract similar documents |
| Oleg Semenovich Levin, V K Datiyeva | ||
| "... amantadine, 4 had a fixed-dose of rasagi- line. The dose titration of Requip Modutab was 4 to 8 weeks ..." | ||
| Vol 11, No 2 (2019) | Vascular factors in the genesis of dementia and the optimization of patient management | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov | ||
| Vol 6, No 3 (2014) | Alcohol abuse and related disorders treatment of alcohol dependence | Abstract similar documents |
| Yu. P. Sivolap | ||
| "... these agents, nalmefene that is being registered in Russia. Memantine and a number of other medications ..." | ||
| Vol 16, No 2 (2024) | Alzheimer's disease: diagnosis and treatment, errors in patient management | Abstract similar documents |
| V. A. Parfenov, D. A. Grishina, A. Yu. Tyurina | ||
| "... blocker memantine are used as drugs that improve the cognitive functions of patients with AD. Dispersible ..." | ||
| Vol 12, No 5 (2020) | NMDA receptor antagonists in the treatment of neurological diseases | Abstract similar documents |
| I. S. Preobrazhenskaya | ||
| "... in childhood. The paper describes a clinical case illustrating the use of akatinol memantine in a child ..." | ||
| Vol 8, No 2 (2016) | Alzheimer's disease under the mask of stroke | Abstract similar documents |
| A. A. Naumenko, N. V. Vakhnina | ||
| "... that are unassociated with emotional problems and disturbance of consciousness. Akatinol memantine is a drug that can ..." | ||
| Vol 8, No 4 (2016) | ALZHEIMER’S DISEASE: DIAGNOSIS AND TREATMENT | Abstract similar documents |
| A. A. Naumenko, D. O. Gromova, N. V. Trofimova, I. S. Preobrazhenskaya | ||
| Vol 7, No 1 (2015) | Outpatient management of patients with dyscirculatory encephalopathy | Abstract similar documents |
| V. A. Parfenov, D. V. Neverovsky | ||
| "... at preventing stroke and improving cognitive functions; moreover, akatinol memantine was noted to be effective ..." | ||
| Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Non-drug therapies for cognitive impairment | Abstract similar documents |
| I. S. Preobrazhenskaya, D. Fantalis, S. A. Abdyshova, A. A. Kindarova | ||
| Vol 3, No 4 (2011) | Current therapy for cognitive impairments | Abstract similar documents |
| N. V. Vakhnina | ||
| "... , neurometabolic, and noradrenergic agents. The indication for the use of memantine and/or acetylcholinergic agents ..." | ||
| Vol 4, No 1 (2012) | Lewy body dementia: clinical manifestations, diagnosis, and treatment | Abstract similar documents |
| Irina Sergeyevna Preobrazhenskaya | ||
| "... memantine in the patients with LBD are described in detail. ..." | ||
| Vol 5, No 1 (2013) | Mild and moderate cognitive impairments: clinical manifestations, etiology, pathogenesis, treatment approaches | Abstract similar documents |
| Irina Sergeyevna Preobrazhenskaya | ||
| "... of an interregional study of the efficacy of akatinol memantine in patients with MCI of varying etiology are given. ..." | ||
| Vol 11, No 3 (2019) | he amyloid hypothesis of Alzheimer's disease: past and present, hopes and disappointments | Abstract similar documents |
| I. V. Litvinenko, A. Yu. Emelin, V. Yu. Lobzin, K. A. Kolmakova, K. M. Naumov, I. A. Lupanov, G. A. Kilivaeva, M. R. Alizade | ||
| "... (Akatinol memantine, an inhibitor of NMDA receptors and glutamatergic excitotoxicity) for the treatment ..." | ||
| Vol 4, No 2S (2012): Сognitive and other neuropsychiatric disorders | Akatinol in the treatment of noncognitive neuropsychological disorders in neurogeriatric diseases | Abstract similar documents |
| T. G. Voznesenskaya | ||
| "... dementia. Memantine (akatinol) therapy-induced changes in NNPDs are shown. It is emphasized ..." | ||
| Vol 10, No 1 (2018) | Sleep disorders and Alzheimer’s disease | Abstract similar documents |
| A. N. Bogolepova | ||
| "... and treating sleep disorders in patients with AD. Akatinol memantine is one of the drugs with proven efficacy ..." | ||
| Vol 13, No 1 (2021) | Cognitive impairment in hypertension | Abstract similar documents |
| Yu. A. Starchina, V. V. Zakharov | ||
| "... of dementia. When dementia develops, reversible NMDA receptor inhibitors (memantine) and central ..." | ||
| Vol 7, No 1 (2015) | Current therapy for chronic cerebrovascular attack | Abstract similar documents |
| A. A. Shmonin, V. S. Krasnov, I. A. Shmonina, E. V. Melnikova | ||
| "... , donepezil) and a reversible NMDA receptor blocker (memantine) are symptomatically used at a stage ..." | ||
| Vol 17, No 3 (2025) | Cognitive impairment in patients with chronic cerebral ischemia (discirculatory encephalopathy) | Abstract similar documents |
| V. A. Parfenov, E. V. Silina | ||
| "... , galantamine) and the glutamate receptor antagonist memantine. The efficacy and safety of choline alfoscerate ..." | ||
| Vol 15, No 1 (2023) | Management of patients with cognitive impairment | Abstract similar documents |
| V. A. Parfenov | ||
| "... , galantamine) and the glutamate receptor blocker memantine are used. The use of choline alfoscerate in CI ..." | ||
| Vol 6, No 1 (2014) | Severe dementia: diagnosis, patient management, prevention of complications | Abstract similar documents |
| A.B. Lokshina | ||
| "... dementia with acetylcholinesterase inhibitors and/or a competitive blocker of the NMDA-receptor, memantine ..." | ||
| 1 - 53 of 53 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
